Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Evaluation of SARS-CoV-2 anti-Spike antibody levels and breakthrough infection risk among vaccinated adults in North Lebanon. Local targets link to admitted publications; unresolved targets remain external evidence.
The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures.
10.3346/jkms.2020.35.e61 · 2020 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
External reference
Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
10.3389/fimmu.2020.01949 · 2020 · External reference
Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers
2004 · External reference
Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients
10.1007/bf02256554 · 2004 · External reference
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
10.1056/nejmoa2027906 · 2020 · External reference
First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers
2021 · External reference
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
10.1038/s41586-020-2608-y · 2020 · External reference
A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India.
10.1016/j.eclinm.2021.101038 · 2021 · External reference
A Review of Different Vaccines and Strategies to Combat COVID-19
2022 · External reference
An update on the global vaccine development for coronavirus
10.1016/j.dsx.2020.10.023 · 2020 · External reference
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
10.1016/s0140-6736(21)00234-8 · 2021 · External reference
Evaluation and Comparison of Serological Methods for COVID-19 Diagnosis
10.3389/fmolb.2021.682405 · 2021 · External reference
Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics
10.1515/cclm-2020-0443 · 2020 · External reference
Comparison of the performance of a chemiluminescence assay and an ELISA for detection of anti-GBM antibodies
10.1080/0886022x.2019.1702056 · 2020 · External reference
Unresolved reference
2020 · External reference
Unresolved reference
2021 · External reference
Unresolved reference
2021 · External reference
Antibody response to mRNA SARS-CoV-2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation
10.1111/tid.13828 · 2022 · External reference
SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients
10.1016/j.cgh.2021.09.003 · 2022 · External reference
Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay
10.1016/j.jcv.2021.104820 · 2021 · External reference
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
10.1056/nejmc2111462 · 2021 · External reference
Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population
2021 · External reference
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
10.1016/s2213-2600(21)00220-4 · 2021 · External reference
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
10.1016/s0140-6736(21)02183-8 · 2021 · External reference
Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose.
2022 · External reference
Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination
10.1093/cid/ciab381 · 2021 · External reference
Assessment of Post-Vaccination Antibody Response Eight Months after the Administration of BNT1622b2 Vaccine to Healthcare Workers with Particular Emphasis on the Impact of Previous COVID-19 Infection.
2021 · External reference
Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021.
10.2807/1560-7917.es.2021.26.12.2100329 · 2021 · External reference
Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination.
10.3390/cells10081952 · 2021 · External reference
The Role of Lebanon in the COVID-19 Butterfly Effect: The B.1.398 Example.
10.3390/v14081640 · 2022 · External reference
Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.
10.3389/fimmu.2022.1062067 · 2022 · External reference
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
10.1056/nejmoa2108891 · 2021 · External reference
Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium.
10.3390/v14040802 · 2022 · External reference
COVID-19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan: A retrospective cohort study
10.1002/jmv.27985 · 2022 · External reference
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
10.1038/s41577-021-00662-4 · 2022 · External reference
The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmission.
2021 · External reference
The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster.
10.2147/idr.s390351 · 2022 · External reference
SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA
10.3201/eid2810.221058 · 2022 · External reference
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
10.1038/s41591-021-01413-7 · 2021 · External reference
Covid-19 Vaccine Effectiveness in New York State
10.1056/nejmoa2116063 · 2022 · External reference
SARS-CoV-2 Vaccine Breakthrough Infections of Omicron and Delta Variants in Healthcare Workers.
2023 · External reference
Breakthrough SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa.
10.1016/s0140-6736(22)01190-4 · 2022 · External reference
Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers.
2021 · External reference
